SANTA MONICA, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that Roger Crystal, M.D., Opiant’s Chief Executive Officer, will provide a corporate update at the Cantor Global Healthcare Conference, being held October 1-3 in New York City.
|Opiant Presentation Details
||Wednesday, October 3
||10:55am Eastern Time
||InterContinental New York Barclay Hotel
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose. The National Institute on Drug Abuse, a component of the NIH, describes addictive disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Opiant's first drug overdose product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by its commercialization partner, Adapt Pharmaceuticals. For more information please visit: www.opiant.com.
For Media Inquiries:
Julie Normart, W2O Group
For Investor Relations:
LifeSci Advisors, LLC
Source: Opiant Pharmaceuticals, Inc.